Related Experiment Video
Updated: Mar 20, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Advanced interstitial chemotherapy for treating malignant glioma
Yuan-Yun Tseng1,2, Yi-Chuan Kau3, Shih-Jung Liu4,5
1a Department of Neurosurgery, Shuang Ho Hospital , Taipei Medical University , Taipei , Taiwan.
Expert Opinion on Drug Delivery
|June 2, 2016
Summary
Glioblastoma multiforme (GBM) treatment shows limited survival benefits with current methods. Emerging nanobiotechnology and drug delivery systems offer potential for improved glioblastoma multiforme therapies.
Area of Science:
- Neuro-oncology
- Drug Delivery Systems
- Nanobiotechnology
Background:
- Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with a poor prognosis.
- Current multimodal treatments including surgery, radiation, and chemotherapy offer limited survival benefits for GBM patients.
- Interstitial biodegradable carmustine wafers (Gliadel) provide marginal survival improvements for select malignant glioma patients.
Purpose of the Study:
- To summarize recent advancements in glioblastoma multiforme treatment.
- To present emerging research and future directions in GBM therapy.
- To provide an overview of preclinical developments, clinical efficacy, safety, and future research avenues.
Main Methods:
- Review of recent representative studies on GBM treatment.
- Analysis of preclinical developments and clinical trial data.
- Exploration of emerging nanobiotechnology and polymeric material science applications.
Main Results:
- Current interstitial chemotherapy (Gliadel) offers only a modest survival benefit (approx. 2 months).
- Ongoing studies explore combining chemotherapy with antiangiogenesis, gene therapy, and growth factors.
- Nanocarrier-based noninvasive techniques show promise for enhanced GBM treatment efficacy.
Conclusions:
- Significant improvements in GBM treatment efficacy are still needed.
- Nanobiotechnology and advanced drug delivery systems are key areas for future GBM research.
- Developing novel therapeutic strategies is crucial to improve outcomes for glioblastoma multiforme patients.
